These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39073262)

  • 1. Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple-Negative Breast Cancer.
    Tian W; Zhu L; Luo Y; Tang Y; Tan Q; Zou Y; Chen K; Deng X; Tang H; Li H; Cai M; Xie X; Ye F
    Adv Sci (Weinh); 2024 Sep; 11(36):e2309903. PubMed ID: 39073262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.
    Lin Y; Zhang J; Li Y; Guo W; Chen L; Chen M; Chen X; Zhang W; Jin X; Jiang M; Xiao H; Wang C; Song C; Fu F
    J Transl Med; 2022 Jan; 20(1):17. PubMed ID: 34991621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.
    Deng L; Liao L; Zhang YL; Hu SY; Yang SY; Ma XY; Huang MY; Zhang FL; Li DQ
    Cancer Lett; 2023 Apr; 560():216124. PubMed ID: 36907504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
    Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Liu L; Chen Y; Zhang T; Cui G; Wang W; Zhang G; Li J; Zhang Y; Wang Y; Zou Y; Ren Z; Xue W; Sun R
    Adv Sci (Weinh); 2024 May; 11(20):e2302379. PubMed ID: 38566431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP1-mediated deubiquitination of KDM1A promotes the malignant progression of triple-negative breast cancer.
    Su Y; Du Y; He W
    J Biochem Mol Toxicol; 2024 Oct; 38(10):e23864. PubMed ID: 39318028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3K27ac-induced RHOXF2 activates Wnt2/β-catenin pathway by binding to HOXC13 to aggravate the malignant progression of triple negative breast cancer.
    Guo M; Wang R; Nie M; Zhang H; Wang C; Song C; Niu S
    Cell Signal; 2024 Aug; 120():111196. PubMed ID: 38697448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
    Huang MY; Hu SY; Dong J; Deng L; Andriani L; Ma XY; Zhang YL; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2024 Aug; 84(16):2660-2673. PubMed ID: 38748783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
    Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
    Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells.
    Koh M; Lim H; Jin H; Kim M; Hong Y; Hwang YK; Woo Y; Kim ES; Kim SY; Kim KM; Lim HK; Jung J; Kang S; Park B; Lee HB; Han W; Lee MS; Moon A
    Autophagy; 2024 Mar; 20(3):659-674. PubMed ID: 38290972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
    Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
    J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression.
    Lim JP; Nair S; Shyamasundar S; Chua PJ; Muniasamy U; Matsumoto K; Gunaratne J; Bay BH
    Cancer Lett; 2019 Jun; 452():119-131. PubMed ID: 30905819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality.
    Zhang W; Xia D; Li Z; Zhou T; Chen T; Wu Z; Zhou W; Li Z; Li L; Xu J
    Cell Death Dis; 2019 Aug; 10(8):606. PubMed ID: 31406104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
    Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
    Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.